MA39524A1 - 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs - Google Patents

1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs

Info

Publication number
MA39524A1
MA39524A1 MA39524A MA39524A MA39524A1 MA 39524 A1 MA39524 A1 MA 39524A1 MA 39524 A MA39524 A MA 39524A MA 39524 A MA39524 A MA 39524A MA 39524 A1 MA39524 A1 MA 39524A1
Authority
MA
Morocco
Prior art keywords
naphthyridin
ones used
antiproliferative compounds
compounds
ones
Prior art date
Application number
MA39524A
Other languages
English (en)
Inventor
Amala Kompella
Venugopala Krishna Gampa
Srinivasulu Ganganamoni
Balakrishna Reddy Sirigireddy
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52589723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39524(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MA39524A1 publication Critical patent/MA39524A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouvelles 1h-1,8-naphthyridin-2-ones antiprolifératives de formule générale (i) ou des sels pharmaceutiquement acceptables de celles-ci, dans lesquelles les groupes variables sont tels que définis dans la description, et leur préparation et leur utilisation dans le traitement thérapeutique de troubles liés à l'inhibition de tyrosine kinases chez les animaux à sang chaud. Ces composés peuvent surmonter la résistance aux médicaments induite par l'imatinib.
MA39524A 2014-06-06 2016-12-05 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs MA39524A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2781CH2014 2014-06-06
PCT/IN2014/000777 WO2015186137A1 (fr) 2014-06-06 2014-12-15 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs

Publications (1)

Publication Number Publication Date
MA39524A1 true MA39524A1 (fr) 2018-01-31

Family

ID=52589723

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39524A MA39524A1 (fr) 2014-06-06 2016-12-05 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs

Country Status (18)

Country Link
US (2) US9765072B2 (fr)
EP (1) EP3152205A1 (fr)
JP (1) JP2017516867A (fr)
KR (1) KR20170016921A (fr)
CN (1) CN106573929A (fr)
AP (1) AP2016009604A0 (fr)
AU (1) AU2014396394A1 (fr)
BR (1) BR112016028674A2 (fr)
CA (1) CA2950250A1 (fr)
CL (1) CL2016003102A1 (fr)
EA (1) EA201692371A1 (fr)
HK (1) HK1231469A1 (fr)
IL (1) IL249118A0 (fr)
MA (1) MA39524A1 (fr)
MX (1) MX2016015350A (fr)
PH (1) PH12016502432A1 (fr)
SG (1) SG11201610149YA (fr)
WO (1) WO2015186137A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201610149YA (en) * 2014-06-06 2017-01-27 Natco Pharma Ltd 1h-1,8- naphthyridin-2ones as anti proliferative compounds
CN107663151B (zh) * 2016-07-28 2021-11-26 江苏豪森药业集团有限公司 甲磺酸氟马替尼的中间体合成方法
CN108473476B (zh) * 2016-10-13 2021-02-19 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基杂环类化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034598B1 (ru) 2005-12-23 2020-02-25 Ариад Фармасьютикалз, Инк. Применение бициклических гетероарильных соединений для лечения рака
CN101489558A (zh) * 2006-05-08 2009-07-22 阿里亚德医药股份有限公司 炔类杂芳基化合物
CN103435595A (zh) * 2006-05-08 2013-12-11 阿里亚德医药股份有限公司 炔类杂芳基化合物
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2011090738A2 (fr) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
KR101347303B1 (ko) 2010-01-29 2014-01-06 한미사이언스 주식회사 단백질 키나아제 저해활성을 갖는 티에노[3,2-ｄ]피리미딘 유도체
SG11201610149YA (en) * 2014-06-06 2017-01-27 Natco Pharma Ltd 1h-1,8- naphthyridin-2ones as anti proliferative compounds

Also Published As

Publication number Publication date
US9765072B2 (en) 2017-09-19
AP2016009604A0 (en) 2016-12-31
SG11201610149YA (en) 2017-01-27
PH12016502432A1 (en) 2017-03-06
US20170349588A1 (en) 2017-12-07
BR112016028674A2 (pt) 2017-08-22
WO2015186137A1 (fr) 2015-12-10
EA201692371A1 (ru) 2017-04-28
EP3152205A1 (fr) 2017-04-12
MX2016015350A (es) 2017-05-10
JP2017516867A (ja) 2017-06-22
KR20170016921A (ko) 2017-02-14
CL2016003102A1 (es) 2017-06-23
CA2950250A1 (fr) 2015-12-10
US10047088B2 (en) 2018-08-14
CN106573929A (zh) 2017-04-19
AU2014396394A1 (en) 2016-12-08
US20170114057A1 (en) 2017-04-27
HK1231469A1 (zh) 2017-12-22
IL249118A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
PH12016500531B1 (en) Compound inhibiting activities of btk and/or jak3 kinases
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
EA201791941A1 (ru) Бициклические кетосульфонамидные соединения
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
MX393057B (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas.
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
WO2016109217A3 (fr) Inhibiteurs de la btk
MX387443B (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA201790870A1 (ru) Трициклические атропоизомерные соединения
WO2017134685A3 (fr) Nouveaux composés hydrazino utilisés comme inhibiteurs de btk
MA39524A1 (fr) 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MX2015016539A (es) 4-(5-(4-clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol -3-il)bencenosulfonamida como modulador de nachr alfa 7.
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
WO2017168454A3 (fr) Nouveaux composés utilisés comme inhibiteurs de btk
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
GEAP202416375A (en) Pro drugs of pde10 compounds